Literature DB >> 29473715

Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis.

John D Pauling1, Robyn T Domsic2, Lesley A Saketkoo3, Celia Almeida4, Jane Withey5, Hilary Jay5, Tracy M Frech6, Francesca Ingegnoli7, Emma Dures4, Joanna Robson4, Neil J McHugh1, Ariane L Herrick8, Marco Matucci-Cerinic9, Dinesh Khanna10, Sarah Hewlett4.   

Abstract

OBJECTIVE: Raynaud's phenomenon (RP) is the most common manifestation of systemic sclerosis (SSc). RP is an episodic phenomenon, not easily assessed in the clinic, leading to reliance on self-report. A thorough understanding of the patient experience of SSc-RP is essential to ensuring that patient-reported outcome (PRO) instruments capture domains important to the target patient population. We report the findings of an international qualitative research study investigating the patient experience of SSc-RP.
METHODS: Focus groups of SSc patients were conducted across 3 scleroderma centers in the US and UK, using a topic guide and a priori purposive sampling framework devised by qualitative researchers, SSc patients, and SSc experts. Focus groups were audio recorded, transcribed, anonymized, and analyzed using inductive thematic analysis. Focus groups were conducted until thematic saturation was achieved.
RESULTS: Forty SSc patients participated in 6 focus groups conducted in Bath (UK), New Orleans (Louisiana), and Pittsburgh (Pennsylvania). Seven major themes were identified that encapsulate the patient experience of SSc-RP: physical symptoms, emotional impact, triggers and exacerbating factors, constant vigilance and self-management, impact on daily life, uncertainty, and adaptation. The interrelationship of the 7 constituent themes can be arranged within a conceptual map of SSc-RP.
CONCLUSION: We have explored the patient experience of SSc-RP in a diverse and representative SSc cohort and identified a complex interplay of experiences that result in significant impact. Work to develop a novel PRO instrument for assessing the severity and impact of SSc-RP, comprising domains/items grounded in the patient experiences of SSc-RP identified in this study, is underway.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Year:  2018        PMID: 29473715      PMCID: PMC5962378          DOI: 10.1002/acr.23475

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  28 in total

1.  Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.

Authors:  B Coleiro; S E Marshall; C P Denton; K Howell; A Blann; K I Welsh; C M Black
Journal:  Rheumatology (Oxford)       Date:  2001-09       Impact factor: 7.580

Review 2.  Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.

Authors:  Vasileios Botzoris; Alexandros A Drosos
Journal:  Joint Bone Spine       Date:  2010-12-22       Impact factor: 4.929

3.  Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon.

Authors:  M V Kyle; G Belcher; B L Hazleman
Journal:  J Rheumatol       Date:  1992-09       Impact factor: 4.666

4.  Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary.

Authors:  John D Pauling; Jacqueline A Shipley; Darren J Hart; Anita McGrogan; Neil J McHugh
Journal:  J Rheumatol       Date:  2015-06-01       Impact factor: 4.666

5.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Authors:  M Dziadzio; C P Denton; R Smith; K Howell; A Blann; E Bowers; C M Black
Journal:  Arthritis Rheum       Date:  1999-12

6.  A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis.

Authors:  A L Herrick; S Hollis; D Schofield; F Rieley; A Blann; K Griffin; T Moore; J M Braganza; M I Jayson
Journal:  Clin Exp Rheumatol       Date:  2000 May-Jun       Impact factor: 4.473

7.  Updating the OMERACT filter: implications for patient-reported outcomes.

Authors:  John R Kirwan; Susan J Bartlett; Dorcas E Beaton; Maarten Boers; Ailsa Bosworth; Peter M Brooks; Ernest Choy; Maarten de Wit; Francis Guillemin; Sarah Hewlett; Tore K Kvien; Robert B Landewé; Amye L Leong; Anne Lyddiatt; Lyn March; James May; Pamela Lesley Montie; Enkeleida Nikaï; Pam Richards; Marieke M J H Voshaar; Wilma Smeets; Vibeke Strand; Peter Tugwell; Laure Gossec
Journal:  J Rheumatol       Date:  2014-03-01       Impact factor: 4.666

8.  The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.

Authors:  V D Steen; T A Medsger
Journal:  Arthritis Rheum       Date:  1997-11

9.  Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.

Authors:  C M Black; L Halkier-Sørensen; J J Belch; S Ullman; R Madhok; A J Smit; J D Banga; H R Watson
Journal:  Br J Rheumatol       Date:  1998-09

10.  Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2).

Authors:  P M Dowd; M F Martin; E D Cooke; S A Bowcock; R Jones; P A Dieppe; J D Kirby
Journal:  Br J Dermatol       Date:  1982-01       Impact factor: 9.302

View more
  15 in total

Review 1.  Qualitative Methods to Advance Care, Diagnosis, and Therapy in Rheumatic Diseases.

Authors:  Lesley Ann Saketkoo; John D Pauling
Journal:  Rheum Dis Clin North Am       Date:  2018-02-21       Impact factor: 2.670

2.  Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?

Authors:  Michael Hughes; Dinesh Khanna; John D Pauling
Journal:  Rheumatology (Oxford)       Date:  2020-03-01       Impact factor: 7.580

Review 3.  Raynaud's phenomenon.

Authors:  Ariane L Herrick
Journal:  J Scleroderma Relat Disord       Date:  2019-02-13

Review 4.  Patient-reported outcome instruments in clinical trials of systemic sclerosis.

Authors:  John D Pauling; Joana Caetano; Corrado Campochiaro; Giacomo De Luca; Ana Maria Gheorghiu; Maria Grazia Lazzaroni; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2019-11-25

Review 5.  A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc.

Authors:  Lesley Ann Saketkoo; Tracy Frech; Cecília Varjú; Robyn Domsic; Jessica Farrell; Jessica K Gordon; Carina Mihai; Nora Sandorfi; Lee Shapiro; Janet Poole; Elizabeth R Volkmann; Monika Lammi; Kendra McAnally; Helene Alexanderson; Henrik Pettersson; Faye Hant; Masataka Kuwana; Ami A Shah; Vanessa Smith; Vivien Hsu; Otylia Kowal-Bielecka; Shervin Assassi; Maurizio Cutolo; Cristiane Kayser; Victoria K Shanmugam; Madelon C Vonk; Kim Fligelstone; Nancy Baldwin; Kerri Connolly; Anneliese Ronnow; Beata Toth; Maureen Suave; Sue Farrington; Elana J Bernstein; Leslie J Crofford; László Czirják; Kelly Jensen; Monique Hinchclif; Marie Hudson; Matthew R Lammi; Jennifer Mansour; Nadia D Morgan; Fabian Mendoza; Mandana Nikpour; John Pauling; Gabriela Riemekasten; Anne-Marie Russell; Mary Beth Scholand; Elise Seigart; Tatiana Sofia Rodriguez-Reyna; Laura Hummers; Ulrich Walker; Virginia Steen
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-09-15       Impact factor: 4.991

Review 6.  Practical management of Raynaud's phenomenon - a primer for practicing physicians.

Authors:  Ahmad Ramahi; Michael Hughes; Dinesh Khanna
Journal:  Curr Opin Rheumatol       Date:  2022-06-09       Impact factor: 4.941

7.  Impact of Covid-19 on clinical care and lived experience of systemic sclerosis: An international survey from EURORDIS-Rare Diseases Europe.

Authors:  Michael Hughes; John D Pauling; Andrew Moore; Jennifer Jones
Journal:  J Scleroderma Relat Disord       Date:  2021-03-16

8.  Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study✰,✰✰,★,★★.

Authors:  Alain Lescoat; Susan L Murphy; Yen T Chen; Nadia Vann; Francesco Del Galdo; David Cella; Maya H Buch; Dinesh Khanna
Journal:  Semin Arthritis Rheum       Date:  2021-11-07       Impact factor: 5.431

9.  Raynaud's phenomenon.

Authors:  Ashraful Haque; Michael Hughes
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

10.  An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.

Authors:  Murray Baron; Bashar Kahaleh; Elana J Bernstein; Lorinda Chung; Philip J Clements; Christopher Denton; Robyn T Domsic; Nava Ferdowsi; Ivan Foeldvari; Tracy Frech; Jessica K Gordon; Marie Hudson; Sindhu R Johnson; Dinesh Khanna; Zsuzsannah McMahan; Peter A Merkel; Sonali Narain; Mandana Nikpour; John D Pauling; Laura Ross; Antonia Maria Valenzuela Vergara; Alessandra Vacca
Journal:  J Scleroderma Relat Disord       Date:  2018-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.